New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer Roche announced today that SATURN, a ...
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer First EGFR Targeted and Oral Therapy to Improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results